Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure Athanassios Argiris, Daniel J. Haraf, Merrill S. Kies, Everett E. Vokes Oncologist 2003; 8: 350-360 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in head and neck cancers and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the results of multicenter trials with chemoradiotherapy with 5-FU- and hydroxyurea-based regimens for the treatment of locoregionally advanced head and neck cancer. Explain the rationale for the combination treatment of radiation, 5-FU, and hydroxyurea. Recognize the toxicities and potential functional impairment for patients treated with aggressive concurrent chemoradiotherapy. Discuss the experimental role of induction chemotherapy in the management of locoregionally advanced head and neck cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 1, 2003 Most Recent Review: Aug. 1, 2003* Most Recent Update: Aug. 1, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.